Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease
- 1 May 2017
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (5) , 1641-1649.e6
Abstract
No abstract availableKeywords
Funding Information
- Assistance Publique des Hôpitaux de Paris
- Net4CGD consortium
This publication has 35 references indexed in Scilit:
- Treatment With Anakinra, a Recombinant IL-1 Receptor Antagonist, Unlikely to Induce Lasting Remission in Patients With CGD ColitisAmerican Journal of Gastroenterology, 2015
- mTOR: a pharmacologic target for autophagy regulationJournal of Clinical Investigation, 2015
- Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous diseaseJournal of Allergy and Clinical Immunology, 2014
- IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humansProceedings of the National Academy of Sciences, 2014
- The mTOR pathway and integrating immune regulationImmunology, 2013
- Chronic Granulomatous DiseaseHematology/Oncology Clinics of North America, 2013
- Complications of Tumor Necrosis Factor–α Blockade in Chronic Granulomatous Disease–Related ColitisClinical Infectious Diseases, 2010
- Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous diseaseBlood, 2010
- Reactive oxygen species–independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous diseaseProceedings of the National Academy of Sciences, 2010
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003